Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 8/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31191648 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1TSHRMAPK1KCNA3 | |
| SCHEMBL5986722 | 0.80 | KCNA3 (0.36) | KDM4EALDH1A1TSHRMAPK1KCNA3 | |
| SCHEMBL13725473 | 0.80 | KCNA3 (0.39) | KDM4EALDH1A1TSHRMAPK1KCNA3 | |
| SCHEMBL17321059 | 0.80 | KCNA3 (0.36) | KDM4EALDH1A1TSHRMAPK1KCNA3 | |
| SCHEMBL30933173 | 0.76 | ALDH1A1 (0.34) | KDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL5988056 | 0.71 | HTR2A (0.41) | — | |
| SCHEMBL5985858 | 0.71 | SMN1; SMN2 (0.36) | KDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL30395048 | 0.71 | ACHE (0.39) | ALDH1A1KCNA3 | |
| SCHEMBL289277 | 0.71 | ACHE (0.39) | ALDH1A1KCNA3 | |
| SCHEMBL21632934 | 0.71 | ALDH1A1 (0.47) | KDM4EALDH1A1TSHRMAPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KDM4E 1907/4885ALDH1A1 504/4885TSHR 1555/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | KDM4E 1907/4885ALDH1A1 504/4885TSHR 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.